Arthi Kanthasamy

PhD
John G. Salsbury Chair in Veterinary Medicine
Professor
515-294-7238
1083 Vet Med
Education & Certifications  
  • BS, Biochemistry, 1990, PSG College of Sciences, India
  • PhD, Medicinal Chemistry and Molecular Pharmacology, 2001, Purdue University, W. Lafayette, IN
Teaching  

  • 2007-2015                          Instructor, BMS 354/554, General Pharmacology


  • 2007-Present                       Instructor, BMS 329, Physiology and Functional Anatomy of Domestic Animals


  • 2007-Present                       Instructor, TOX 501, Principles of Toxicology


  • 2014-Present                       Instructor, BMS 539X, Principles of Pharmacology


  • 2013-Present                       Instructor, BMS 538X, Principles of Physiology

Research Focus & Interests  
  • Oxidative stress
  • Parkinson’s Disease
  • Cerebral Ischemia
  • Neuroinflammatory events
  • Dopamine

 

Dr. Arthi Kanthasamy’s research focuses on the cellular and molecular mechanisms underlying neurodegenerative processes associated with cerebral ischemia, drugs of abuse, and Parkinsons’s disease.  Brain ischemic damage results from occlusion of cerebral arteries that supply brain cells.  If the blockade is not reversed within a defined short period, it leads to induction of cell death within the region that is supplied by the affected vessels.  The goals of her lab are two fold: 1)  To elucidate the role of novel PKC isoform cell signaling events in apoptotic death of striatal neurons; 2)  To evaluate the influence of excessive dopamine in striatal neuronal oxidative damage during cerebral ischemia. 

Parkinson’s disease is a progressive age related neurodegenerative disease characterized by pronounced loss of the dopaminergic neurons in the substantia nigra pars compacta (SNc).  To identify the cellular mechanisms underlying selective loss of dopaminergic neurons in PD, Dr. Kanthasamy has collaborated to developed a unique in vitro dopaminergic cell culture model to study the importance of autophagic degradative machinery in dopaminergic neuronal loss.  Her recent studies indicate a functional link between the ubiquitin proteasomal system and autophagy.  A dynamic balance between the two degradative machineries is essential for the normal functioning of the cell.  Therefore, she is interested in examining the functional interaction between the two protein degradation systems in a chemical-induced model of Parkinson’s disease.  The dopaminergic toxicant methamphetamine is used as a key inducer of autophagy and apoptosis.  She is studying the signal transduction mechanisms associated with cross talk between autophagy and apoptosis in mediating neuronal degeneration. Genetic, proteomic, biochemical, cell biological,  pharmacological, neurochemical, behavioral and electron microscopic (TEM) approaches.  Currently, Dr. Kanthasamy is collaborating with Dr. Syed Ali at the National Center for Toxicological Research, United States Food and Drug Administration at Arkansas.

Another major focus of her research is to understand the role of neuroinflammatory events in PD induced dopaminergic neuronal loss.  She is studying the functional interaction between activated microglia and dopaminergic neurodegeneration in experimental models of Parkinson’s disease.  Understanding the cellular events underlying microglia-mediated neurodegeneration may be critical in developing novel therapeutic strategies that limit the progressive loss of dopaminergic neurons in PD related chronic neurodegenerative disease.

Honors & Awards  

In 2009, Dr. Kanthasamy received funding from the NINDS’ “New Investigator Award” program. She will receive a total of $1.28 million for her work in researching brain inflammatory mechanisms of Parkinson ’s disease models.   

National Institutes of Health, NINDS “New Investigator Award,” 2009

Young Scientist Award, Association of Scientists of Indian Origin in America -Neuroscience Division, 2006

Outstanding Research Presentation Award at Purdue University Neuroscience (PUN) Retreat, 1999

Summer fellowship from Parkinson’s Disease Foundation for the project titled, “Mechanisms of neuroprotective effect of strychnine-insensitive glycine site antagonists in an experimental Parkinson’s model: Effects on cellular bioenergtics and MPP+ bio-disposition, 1996

Summer fellowship from Parkinson’s Disease Foundation for the project titled, “Biochemical, behavioral and histological characterization of strychnine-insensitive glycine site antagonists in an experimental Parkinson’s model,” 1995

Leadership/Committees/Council  
  • BIG DATA BRAIN INITIATIVE (BDBI) review committee (2016)
  • University Career awards committee (2016).
  • ISU Bailey awards: Grant reviewer (2016).
  • CVM Research Symposium organizing committee (2016).
  • Served on the CVM-grant review committee and Chaired CVM seed grant review session 2016.
  • Served as Chair of Research advisory committee (RAC) College of Veterinary Medicine (2014-Present).
  • Served as co-chair of Research advisory committee (RAC) College of Veterinary Medicine (2013-2014).
  • Served on the CVM-grant review committee and Chaired IHLAC grant review session 2013.
  • Served on the University Grant review Committee-NSF pre-proposal and Keck grant review 2013.
  • Associate Chair, Interdepartmental Toxicology Graduate Program, 2012-present.
  • Member of the BMS department, Research and Graduate Education Committee (2007-2015).
  • Member of the Curriculum Planning Committee, “Interdepartmental Neuroscience Graduate Program. (2006-2016).
  • Member in the internal grant review panel for formula fund proposal (2007-present).
Memberships  
  1. Society for Neuroscience

  2. Society of Toxicology

Selected Publications  

​Peer Reviewd: 20 selected publications out of over 100. 

  1. Charli A, Jin H, Anantharam V, Kanthasamy A and Kanthasamy AG (2016) Alterations in mitochondrial dynamics induced by tebufenpyrad and pyridaben in a dopaminergic neuronal cell culture model. Neurotoxicology 53:302-313.
  2. Ghosh A, Langley MR, Harischandra DS, Neal ML, Jin H, Anantharam V, Joseph J, Brenza T, Narasimhan B, Kanthasamy A, Kalyanaraman B and Kanthasamy AG (2016) Mitoapocynin Treatment Protects Against Neuroinflammation and Dopaminergic Neurodegeneration in a Preclinical Animal Model of Parkinson's Disease. Journal of neuroimmune pharmacology : 11:259-278.
  3. Gordon R, Neal ML, Luo J, Langley MR, Harischandra DS, Panicker N, Charli A, Jin H, Anantharam V, Woodruff TM, Zhou QY, Kanthasamy AG and Kanthasamy A (2016) Prokineticin-2 upregulation during neuronal injury mediates a compensatory protective response against dopaminergic neuronal degeneration. Nature communications 7:12932.
  4. Gordon R, Singh N, Lawana V, Ghosh A, Harischandra DS, Jin H, Hogan C, Sarkar S, Rokad D, Panicker N, Anantharam V, Kanthasamy AG and Kanthasamy A (2016) Protein kinase Cdelta upregulation in microglia drives neuroinflammatory responses and dopaminergic neurodegeneration in experimental models of Parkinson's disease. Neurobiology of disease 93:96-114.
  5. Kim DS, Jin H, Anantharam V, Gordon R, Kanthasamy A and Kanthasamy AG (2016) p73 gene in dopaminergic neurons is highly susceptible to manganese neurotoxicity. Neurotoxicology.
  6. Rokad D, Ghaisas S, Harischandra DS, Jin H, Anantharam V, Kanthasamy A and Kanthasamy AG (2016) Role of neurotoxicants and traumatic brain injury in alpha-synuclein protein misfolding and aggregation. Brain research bulletin.
  7. Rumbeiha W, Whitley E, Anantharam P, Kim DS and Kanthasamy A (2016) Acute hydrogen sulfide-induced neuropathology and neurological sequelae: challenges for translational neuroprotective research. Annals of the New York Academy of Sciences 1378:5-16.
  8. Ay M, Jin H, Harischandra DS, Asaithambi A, Kanthasamy A, Anantharam V, Kanthasamy AG: Molecular cloning, epigenetic regulation, and functional characterization of Prkd1 gene promoter in dopaminergic cell culture models of Parkinson's disease. J Neurochem 2015;135 (2): 402-15.  Impact Factor: 4.28; Citations: 0.
  9. Panicker N, Saminathan H, Jin H, Neal M, Harischandra DS, Gordon R, Kanthasamy K, Lawana V, Sarkar S, Luo J, Anantharam V, Kanthasamy AG, Kanthasamy A: Fyn Kinase Regulates Microglial Neuroinflammatory Responses in Cell Culture and Animal Models of Parkinson's Disease. J Neurosci 2015;35:10058-10077.  Impact Factor: 6.344; citations: 0.
  10. Jin H, Kanthasamy A, Harischandra DS, Anantharam V, Rana A, Kanthasamy A: Targeted toxicants to dopaminergic neuronal cell death. Methods Mol Biol 2015;1254:239-52. Impact Factor: 1.29; citations: 0.
  11. Harischandra DS, Jin H, Anantharam V, Kanthasamy A, Kanthasamy AG: alpha-Synuclein protects against manganese neurotoxic insult during the early stages of exposure in a dopaminergic cell model of Parkinson's disease. Toxicol Sci 2015;143:454-468. Impact Factor: 3.85; Citations: 2.
  12. Asaithambi A, Ay M, Jin H, Gosh A, Anantharam V, Kanthasamy A, Kanthasamy AG: Protein kinase D1 (PKD1) phosphorylation promotes dopaminergic neuronal survival during 6-OHDA-induced oxidative stress. PLoS One 2014. Cited 4 times. Impact Factor: 3.234; Citations: 3.23.
  13. Harischandra DS, Kondru N, Martin DP, Kanthasamy A, Jin H, Anantharam V, Kanthasamy AG: Role of proteolytic activation of protein kinase Cdelta in the pathogenesis of prion disease. Prion 2014;8:143-153. Impact Factor: 1.96; Citations: 3.
  14. Jin H, Kanthasamy A, Harischandra DS, Kondru N, Ghosh A, Panicker N, Anantharam V, Rana A, Kanthasamy AG: Histone hyperacetylation up-regulates protein kinase Cdelta in dopaminergic neurons to induce cell death: relevance to epigenetic mechanisms of neurodegeneration in Parkinson disease. J Biol Chem 2014;289:34743-34767. Impact Factor: 4.57; Citations: 2. 
  15. Jin H, Kanthasamy A, Ghosh A, Anantharam V, Kalyanaraman B, Kanthasamy AG: Mitochondria-targeted antioxidants for treatment of Parkinson's disease: preclinical and clinical outcomes. Biochim Biophys Acta 2014;1842:1282-1294.  Impact Factor: 4.66; Citations: 15.
  16. Ngwa HA, Kanthasamy A, Jin H, Anantharam V, Kanthasamy AG: Vanadium exposure induces olfactory dysfunction in an animal model of metal neurotoxicity. Neurotoxicology 2014;43:73-81. Impact Factor: 3.37; Citations: 1.
  17. Ghosh A, Saminathan H, Kanthasamy A, Anantharam V, Jin H, Sondarva G, Harischandra DS, Qian Z, Rana A, Kanthasamy AG: The peptidyl-prolyl isomerase Pin1 up-regulation and proapoptotic function in dopaminergic neurons: relevance to the pathogenesis of Parkinson disease. J Biol Chem 2013;288:21955-21971.  Impact Factor: 4.57; Citations: 14.
  18. Chandramani SP, Jin H, Anantharam V, Kanthasamy A, Kanthasamy A: N-Acetyl Cysteine Protects against Methamphetamine-Induced Dopaminergic Neurodegeneration via Modulation of Redox Status and Autophagy in Dopaminergic Cells. Parkinsons Dis 2012;2012:424285. Impact Factor: 2.01; Citations: 2.
  19. Ghosh A, Kanthasamy A, Joseph J, Anantharam V, Srivastava P, Dranka BP, Kalyanaraman B, Kanthasamy AG: Anti-inflammatory and neuroprotective effects of an orally active apocynin derivative in pre-clinical models of Parkinson's disease. J Neuroinflammation 2012;9:241. 241-249. Impact Factor: 4.35; Citations: 21
  20. Gordon R, Anantharam V, Kanthasamy AG, Kanthasamy A: Proteolytic activation of proapoptotic kinase protein kinase Cdelta by tumor necrosis factor alpha death receptor signaling in dopaminergic neurons during neuroinflammation. J Neuroinflammation 2012;9: 82-89. Impact Factor: 4.35; Citations: 13.

Link to PubMed